


Rare Disease
2024-05-11

Thalassemia comprises genetic disorders causing imbalanced globin chain production, leading to anemia and iron issues. Current therapies involve lifelong transfusions, posing health challenges. GemPharmatech has created two mouse models: the NCG-X model, which develops spontaneous anemia and supports human HSC erythroid reconstitution, and globin gene knockout mice, which replicate thalassemia symptoms, making them ideal for testing genetic modifications. These models are pivotal for advancing thalassemia treatment research.
More infomation about blogs

Let us know which event you're attending and we'd be happy to connect with you.
This website will store cookies on your computer. These cookies are used to collect information about how you interact with this website and enable us to remember you. We use this information to improve and customize your browsing experience, as well as to analyze and collect relevant data and metrics about visitors on this website and other platforms. For more information about the cookies we use, please refer to our privacy policy
If you decline, your information will not be tracked when visiting this website. A cookie will be used in your browser to remember your preference settings that you have not accepted.
